Abiomed to Highlight Importance of Optimal PCI Treatment to Improve Outcomes for High-Risk Patients at TCT 2019 – Yahoo Finance

DANVERS, Mass.--(BUSINESS WIRE)--

Abiomed (ABMD) will highlight the benefits of complete revascularization with Protected PCI and the value of Impella protocol-based treatment for survival and native heart recovery in cardiogenic shock patients at the 31st Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco from September 25-29. During the conference, Abiomed will also offer hands-on training to help physicians improve access and closure skills and patient management expertise to achieve improved outcomes.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190917005637/en/

Optimal Outcomes in Complex Patients Are Driven by Enabling Complete Revascularization and Reducing Risk of Acute Kidney Injury

During two breakfast symposia hosted by Abiomed, interventionalists and fellows will present cases and best practices using Impella devices to improve outcomes.

A symposium on Thursday, September 26, will feature best practices for using percutaneous mechanical circulatory support to enable complete revascularization in complex and sick patients.

The schedule for this symposium is below:

A second symposium on Friday, September 27, will highlight the most interesting and complex cases submitted by fellows around the globe. Attendees will learn techniques used for the procedures and how to use hemodynamic support to achieve optimal outcomes.

The schedule for this symposium is below:

Management of Complex PCI Patients: Award Winning Case Presentations

Friday, September 27 6:30-7:45 a.m. PDT Moscone South, Level 2, Room 201-202 Co-Chairs: David Wohns, MD and George Dangas, MD Panelists: Ayaz Rahman, MD; Justin Levisay, MD; Amir Kaki, MD

Improving Outcomes Through Hands-On Training for Interventionalists

At the TCT training pavilion, Abiomed is hosting practical, hands-on workshops on access and closure techniques, achieving complete revascularization with Protected PCI, and implementing AMI cardiogenic shock systems of care. Visit the TCT website to register for training pavilion sessions.

The schedule for these training sessions is included below:

Thursday, September 26

Saturday, September 28

Physicians are also invited to visit booth #1727 to learn about Impella CP with SmartAssist, experience Impella Connect, practice their skills on a simulator, learn about new metrics and algorithms, and have their questions answered by advanced Impella trainers.

Impella CP with SmartAssist is the latest technological development for the Impella platform and is designed to improve patient outcomes with advanced algorithms and simplified patient management. SmartAssist has been commercially available in the U.S. since May, and launched in Europe in August.

Physicians to Share Updated NCSI Study Findings

At TCT 2019, physicians will present the latest results from the National Cardiogenic Shock Initiative (NCSI) Study.

In all, Impella devices will be featured in more than 30 presentations at TCT 2019, focusing on topics such as:

Investor Meeting

Investors are invited to join Abiomeds annual investor meeting on Thursday, September 26. Jeff Popma, MD, will present on: Treating the Complex Patients: Impella Enabled Complete Revascularization. To request attendance, please email ir@abiomed.com.

ABOUT IMPELLA HEART PUMPS

The Impella 2.5 and Impella CP devices are U.S. FDA PMA approved to treat certain advanced heart failure patients undergoing elective and urgent percutaneous coronary interventions (PCI) such as stenting or balloon angioplasty, to re-open blocked coronary arteries. The Impella 2.5, Impella CP, Impella CP with SmartAssist, Impella 5.0 and Impella LD are U.S. FDA approved heart pumps used to treat heart attack or cardiomyopathy patients in cardiogenic shock, and have the unique ability to enable native heart recovery, allowing patients to return home with their own heart. The Impella RP is U.S. FDA approved to treat right heart failure or decompensation following left ventricular assist device implantation, myocardial infarction, heart transplant, or open-heart surgery.

In Europe, the Impella 2.5, Impella CP and Impella CP with SmartAssist are CE marked for treatment of high-risk PCI and AMI cardiogenic shock patients for up to 5 days. Impella 5.0 and Impella LD are CE marked to treat heart attack or cardiomyopathy patients in cardiogenic shock for up to 10 days. The Impella 5.5 heart pump is CE marked to treat heart attack or cardiomyopathy patients in cardiogenic shock for up to 30 days. The Impella RP is CE marked to treat right heart failure or decompensation following left ventricular assist device implantation, myocardial infarction, heart transplant, open-heart surgery, or refractory ventricular arrhythmia.

Story continues

To learn more about the Impella platform of heart pumps, including their approved indications and important safety and risk information associated with the use of the devices, please visit: http://www.impella.com.

ABOUT ABIOMED

Based in Danvers, Massachusetts, USA, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support. Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. For additional information, please visit: http://www.abiomed.com.

Abiomed, Impella, Impella 2.5, Impella 5.0, Impella LD, Impella CP, Impella RP, and Impella Connect are registered trademarks of Abiomed, Inc., and are registered in the U.S. and certain foreign countries. Impella BTR, Impella 5.5, Impella ECP, CVAD Study, and SmartAssist are pending trademarks of Abiomed, Inc.

FORWARD-LOOKING STATEMENTS

This release contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the company's progress toward commercial growth, and future opportunities and expected regulatory approvals. The company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, including the potential for future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, litigation matters, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the company's filings with the Securities and Exchange Commission, including the most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. The company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190917005637/en/

Read the original:

Abiomed to Highlight Importance of Optimal PCI Treatment to Improve Outcomes for High-Risk Patients at TCT 2019 - Yahoo Finance